854 related articles for article (PubMed ID: 31032602)
1. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Rev Cardiovasc Med; 2018 Jun; 19(2):41-49. PubMed ID: 31032602
[TBL] [Abstract][Full Text] [Related]
2. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
3. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
[TBL] [Abstract][Full Text] [Related]
4. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB
Am J Manag Care; 2018 Apr; 24(8 Suppl):S138-S145. PubMed ID: 29693360
[TBL] [Abstract][Full Text] [Related]
5. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
6. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
Nicolucci A; Candido R; Cucinotta D; Graziano G; Rocca A; Rossi MC; Tuccinardi F; Manicardi V
Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779
[TBL] [Abstract][Full Text] [Related]
7. [Outcome studies on SGLT-2 inhibitors].
Seufert J; Laubner K
Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
[TBL] [Abstract][Full Text] [Related]
8. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
9. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
[TBL] [Abstract][Full Text] [Related]
10. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
[TBL] [Abstract][Full Text] [Related]
12. Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium-Glucose Transporter 2 Inhibitors.
Shao H; Shi L; Fonseca VA
Diabetes Care; 2020 Jul; 43(7):1530-1536. PubMed ID: 32345650
[TBL] [Abstract][Full Text] [Related]
13. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis.
Castellana M; Procino F; Sardone R; Trimboli P; Giannelli G
Cardiovasc Diabetol; 2020 Jun; 19(1):87. PubMed ID: 32534590
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
15. How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area.
Canivell S; Mata-Cases M; Vlacho B; Gratacòs M; Real J; Mauricio D; Franch-Nadal J
J Diabetes Res; 2019; 2019():2018374. PubMed ID: 31815146
[TBL] [Abstract][Full Text] [Related]
16. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Fitchett D; Inzucchi SE; Cannon CP; McGuire DK; Scirica BM; Johansen OE; Sambevski S; Kaspers S; Pfarr E; George JT; Zinman B
Circulation; 2019 Mar; 139(11):1384-1395. PubMed ID: 30586757
[TBL] [Abstract][Full Text] [Related]
18. Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study.
Pintat S; Fenici P; Hammar N; Ji L; Khunti K; Medina J; Tang F; Wittbrodt E; Surmont F
BMJ Open Diabetes Res Care; 2019; 7(1):e000627. PubMed ID: 31114700
[TBL] [Abstract][Full Text] [Related]
19. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
[TBL] [Abstract][Full Text] [Related]
20. Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey.
Wong ND; Fan W; Pak J
Diab Vasc Dis Res; 2020; 17(4):1479164120945674. PubMed ID: 32722930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
